Currently out of the existing stock ratings of Gbola Amusa, 23 are a HOLD (21.5%), 73 are a BUY (68.22%), 11 are a SELL (10.28%).

Gbola Amusa

Work Performance Price Targets & Ratings Chart

Analyst Gbola Amusa, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 65.4% that have a potential upside of 51.73% achieved within 273 days.

Gbola Amusa’s has documented 210 price targets and ratings displayed on 25 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on PASG, Passage Bio at 07-Aug-2023.

Wall Street Analyst Gbola Amusa

Analyst best performing recommendations are on SLDB (SOLID BIOSCIENCES LLC).
The best stock recommendation documented was for SLDB (SOLID BIOSCIENCES LLC) at 6/25/2018. The price target of $562.5 was fulfilled within 2 days with a profit of $84.75 (13.09%) receiving and performance score of 65.47.

Average potential price target upside

of $208.2 (53.14%) on SLDB (SOLID BIOSCIENCES LLC).
of $41.05 (121.67%) on KRYS (KRYSTAL BIOTECH).
of $24.62 (72.91%) on MDCO (THE MEDICINES COMPANY).

ADVM Adverum Biotechnologies AXON Axon Enterprise . ESPR Esperion Therapeutics FOLD Amicus Therapeutics KRYS Krystal Biotech LJPC La Jolla Pharmaceutical Co MDCO The Medicines Company MGTX MeiraGTx Holdings PLC MRNA Moderna ONCE Spark Therapeutics PASG Passage Bio PRVB Provention Bio QURE Uniqure NV REGN Regeneron Pharmaceuticals RGNX Regenxbio SAGE Sage Therapeutic SLDB Solid Biosciences LLC VYGR Voyager Therapeutics AGTC Applied Genetic IMVT Immunovant MCRB Seres Therapeutics TSHA Taysha Gene Therapies ABUS Arbutus Biopharma Corp FBRX Forte Biosciences VBLT Vascular Biogenics Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Luca Issi (RBC)